Everest Organics Ltd

Everest Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Everest Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 7 July 2026. This revision reflects a complex interplay of valuation adjustments, deteriorating financial trends, quality concerns, and technical indicators, despite some attractive valuation metrics relative to peers.

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid mixed financial metrics and relative peer comparisons, prompting investors to reassess the stock’s price attractiveness in a volatile sector environment.

Everest Organics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 July 2026, providing investors with the most recent insights into the company’s performance and outlook.

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 24 June 2026. This change is primarily driven by a significant improvement in valuation metrics, despite ongoing challenges in financial performance and market returns. The company’s revised Mojo Score now stands at 31.0, reflecting a cautious but more optimistic outlook.

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a challenging year-to-date performance, the stock’s improved price-to-earnings and price-to-book ratios relative to peers suggest a potential revaluation opportunity for investors willing to navigate its mixed return profile.

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 June 2026. Despite an upgrade in valuation metrics, the company’s overall financial health and market performance continue to raise concerns, prompting a cautious stance among investors.

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, moving from very attractive to attractive territory. Despite a challenging year-to-date performance, the stock’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point relative to its historical averages and peer group, prompting a reassessment of its investment appeal.

Everest Organics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 June 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Everest Organics Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 3 June 2026, reflecting a nuanced shift across key parameters including quality, valuation, financial trend, and technicals. Despite a challenging recent performance, the company’s valuation metrics and certain financial indicators have improved, prompting a reassessment of its market stance.

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive price level. Despite recent price declines and a challenging year-to-date performance, the company’s valuation metrics now present a compelling case for investors seeking value in a volatile market.

Everest Organics Ltd., a Hyderabad-based active pharmaceutical ingredients manufacturer with a market capitalisation of ₹252.00 crores, reported a net profit of ₹2.63 crores for Q4 FY26, marking a significant sequential recovery from ₹0.36 crores in Q3 FY26. However, the stock has plummeted 38.88% over the past year, significantly underperforming the Sensex's 8.40% decline, as investors remain concerned about deteriorating fundamentals and anaemic long-term growth.

Everest Organics Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators amid ongoing fundamental challenges. While the company’s financial trend shows some positive quarterly performance, concerns over long-term profitability and debt servicing continue to weigh on investor sentiment.

Everest Organics Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with the latest insights into the company’s performance and outlook.